Viewing nowN-Pyang Tablet 10 mg (Empagliflozin)
Empagliflozin 10mg
Tablet · Prescription medication
Daehan New Pharm Co., Ltd.

MFDS item code 202102114 · Approved 2021.03.05 · Insurance code 669908490
Improvement of glycemic control in adults with type 2 diabetes
This medication is used to help control blood sugar levels in adult patients with type 2 diabetes mellitus. Initially, it is administered as monotherapy, but in cases where blood sugar control is difficult, it can be used in combination therapy with other antidiabetic agents such as metformin. Particularly, additional administration of this drug improves blood sugar control in patients who do not achieve adequate control with metformin monotherapy or other combination therapies. Furthermore, caution is needed when using this medication in patients with type 2 diabetes who have cardiovascular disease, and it is important to refer to related clinical trial information, etc. This medication aids in comprehensive diabetes management, improving blood sugar control.
The recommended dose of this medicine is 10 mg once daily, whether used as monotherapy or as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions, 3. Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take double the dose in one day. No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well and whose glomerular filtration rate remains < 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. This medicine should be discontinued if the glomerular filtration rate decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those on dialysis, because efficacy is not expected. No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. No dose adjustment based on age is necessary. Renal function and the risk of volume depletion should be considered in patients aged 75 years or older. Initiation of treatment with this medicine is not recommended in patients aged 85 years or older because clinical experience is limited (see Precautions, 4. General Precautions).
This medication should not be administered to patients who have allergic reactions to the active ingredient or any of its components. Additionally, it should not be used in patients with type 1 diabetes or diabetic ketoacidosis. It should not be given to patients with severely impaired renal function, specifically those with a glomerular filtration rate (GFR) of less than 30 mL/min/1.73m2 or who have end-stage renal disease or are undergoing dialysis. Due to the presence of lactose, it should not be given to patients with lactose intolerance or related genetic disorders. Caution is required when using this medication in patients with impaired renal function, and treatment should be avoided in patients with a GFR of less than 60 mL/min/1.73m2. If the GFR continues to drop below 45 mL/min/1.73m2, the medication should be discontinued. The use of this medication is not recommended in heart failure patients classified as NYHA class III-IV, and caution should be exercised in class I-II patients. When used in combination with insulin or sulfonylureas, there is an increased risk of hypoglycemia; therefore, dosage adjustments for insulin or secretagogues may be necessary. While taking this medication, side effects such as hypoglycemia, urinary tract infections, genital infections, increased urination, and depletion of fluid volume may occur, so symptoms should be monitored closely. There is a risk of serious metabolic disturbances such as ketoacidosis, so immediate consultation with healthcare providers is needed if related symptoms (nausea, vomiting, abdominal pain, difficulty breathing, etc.) appear. Elderly patients over 75 years of age have a higher risk of fluid volume loss and require caution, and the use is not recommended in patients over 85 years of age. Additionally, this medication may reduce lithium levels in the blood, so patients undergoing lithium treatment need monitoring of blood levels. It should not be administered to pregnant women, and breastfeeding women should discontinue breastfeeding when taking this medication. The safety and effectiveness in children under 18 years of age have not been established. No specific toxic symptoms have been reported in cases of overdose, but appropriate treatment is necessary depending on the clinical condition. This medication should be kept out of reach of children, and transferring it to another container should be avoided. Caution is needed when driving or operating machinery due to the risk of hypoglycemia. Diabetic patients should take care of regular foot care and genital hygiene and should inform healthcare providers immediately if they experience pain or swelling in the perineum.
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly closed container to protect it from air and moisture. It is recommended to maintain a storage temperature between 1 degree and 30 degrees Celsius.
Light yellow, round, biconvex film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowEmpagliflozin 10mg
Tablet · Prescription medication
Daehan New Pharm Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.